Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Lupus Foundation of America-Supported Phase II Trial Shows Promise for Mesenchymal Stromal Cells as a Potential New Lupus Therapy

      Lupus Foundation of America. (PRNewsFoto/Lupus Foundation of America)

      News provided by

      Lupus Foundation of America, Inc.

      Nov 19, 2026, 10:00 ET

      Share this article

      Share this article


      Results presented at American College of Rheumatology (ACR) Convergence shows positive data with a higher dose of mesenchymal stromal cells for refractory lupus

      WASHINGTON, Nov. 19, 2026 /PRNewswire/ -- New data from the Lupus Foundation of America (LFA)–funded Phase II Mesenchymal Stromal Cells in Systemic Lupus Erythematosus (MiSLE) trial, evaluating a single infusion of umbilical cord-derived mesenchymal stromal cells (MSCs) in adults with active systemic lupus erythematosus (SLE) that had not responded adequately to standard treatment, marks a promising step forward in the search for new treatment options.

      The study, authored by Gary S. Gilkeson, MD, Distinguished University Professor of Medicine, Microbiology, and Immunology at Medical University of South Carolina (MUSC), and co-author/presented by Diane L. Kamen, MD, MSCR, a professor at MUSC, Division of Rheumatology and Immunology, was shared on November 10 in a late-breaking presentation at this year's American College of Rheumatology (ACR) annual meeting. While the trial did not meet its primary efficacy endpoint at 24 weeks with the high dose/low dose groups combined vs placebo, secondary analyses identified significant disease improvement with the higher dose of MSCs with very reassuring safety. These findings warrant a confirmatory trial which is in development.

      "The improvements in lupus activity we observed, especially among patients who received the higher dose, are promising and give us a clearer direction for future research," said Dr. Kamen. "We now intend to test these findings in a confirmatory trial of the higher 5 × 10⁶ cells/kg dose, including evaluation of repeat dosing to determine whether the early responses can be sustained over time."

      Findings to guide the next stage of research

      The primary endpoint was response at Week 24 on a modified SLE Responder Index-4 (SRI-4), which combines measures of disease activity with limits on steroid and other immunosuppressant use. Eighty-one patients were enrolled at nine US Lupus Centers with 27 patients receiving low dose MSCs (one million/kg), 27 receiving high dose MSCs (five million/kg) and 27 receiving placebo. The response measure combined improvement in lupus disease activity with limits on worsening disease and medication use, including a prednisone dose of no more than 10 mg daily beginning at Week 20. At week 24, 38.9% of MSC-treated participants met the modified SRI-4 response criteria, compared with 23.1% receiving placebo a difference of 15.8 percentage points that favored the MSC group but did not reach statistical significance (adjusted p = 0.156).

      Secondary analyses provided additional findings to guide future research:

      Higher-dose response at Week 24: Response rate was 48.1% with 5 million cells/kg versus 29.6% in the lower-dose group and 23.1% in the pooled placebo group. This comparison revealed a 25% difference in response between high dose group and placebo and approached statistical significance (adjusted p = 0.054).

      Earlier response signals: Secondary analyses using the unmodified SRI-4 showed significant benefits between the higher dose and its within-cohort placebo group at Weeks 12, 16 and 20. (p =0.03-0.04 at each time point).

      Per-protocol response: Using analysis by per-protocol response, which excludes patients with major protocol deviations prior to week 24 (for example, having received high-dose steroids for non-lupus indications) the week 24 response was 68.4% (13 of 19) with the higher dose versus 30.0% (6 of 20) in the pooled placebo group (adjusted p = 0.0087).

      Disease activity over time: Scores on the SLE Disease Activity Index (SLEDAI), a measure of lupus disease activity, fell in all three groups. At Week 12, median scores declined by four points in both MSC groups versus two points with placebo. At week 24, the median score of the high dose group was decreased more than the other two groups. After week 24, patients in any of the groups could be treated with any immunosuppressant, biologic or prednisone dose. By Week 52, the low-dose MSC group had the largest median decrease (six points). Differences in baseline disease activity limit direct comparisons between groups.

      Safety findings: Safety was assessed through Week 52. Serious adverse events (SAE) occurred in 27.8% of participants receiving MSCs (44.4% of the low dose cohort and 11.1% of the higher-dose cohort) and 14.8% receiving placebo overall. None of the SAEs were attributed to the study drug. . Serious infections occurred in 7.4% of MSC-treated participants and 3.7% of placebo recipients overall with the high dose MSC group having fewer infections. One death occurred by suicide in the placebo group early in the study. No deaths occurred among the 54 MSC recipients.

      About the MiSLE lupus cell therapy trial

      The MiSLE study is the first multicenter, randomized, double-blind, placebo-controlled trial of allogeneic umbilical cord–derived MSCs in adults with active SLE. These cells come from donor umbilical cord tissue and are being studied for their ability to regulate immune activity. Lupus is a chronic autoimmune disease in which the immune system attacks the body's own tissues and organs.

      Conducted across nine clinical centers, MiSLE evaluated intravenous infusions of either 1 million or 5 million cells per kilogram of body weight, added to standard care. Participants were randomized to MSCs or placebo within two sequential dose cohorts. Of 87 randomized participants, 81 received an infusion: 54 received MSCs and 27 received placebo. The primary efficacy analysis included 80 participants after one placebo participant withdrew consent. Participants had been living with lupus for a median of 12.9 years at enrollment and among the 81 who received an infusion, approximately 89% were female and 36% were Black.

      Building on years of research and community support

      The Lupus Foundation of America has supported MSC research since 2012, including a $3.8 million commitment announced in 2018 for the Phase 2 trial. MiSLE was supported by Lupus Foundation of America and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The Lupus Foundation of America also supported community awareness and participant recruitment.

      "People living with lupus deserve more than treatments that simply manage their symptoms. They deserve new options that offer hope for better disease control, improved quality of life and a future where lupus no longer dictates how they live," said Louise Vetter, President and CEO of the Lupus Foundation of America. "MiSLE reflects years of support in an approach with the potential to address this unmet need. We are extremely encouraged by these findings and deeply grateful to the participants, families and research teams who are helping drive the needle forward towards a cure."

      The study team also acknowledged the investigators and coordinators at all nine clinical sites, the MUSC Data Coordination Unit and Clean Cell Facility, the NIAID research team, and the Data and Safety Monitoring Board.

      To learn more about LFA's longstanding support, funding and involvement with stromal cell research, visit: https://www.lupus.org/our-work/stromal-cell-research

      About the Lupus Foundation of America 

      The Lupus Foundation of America is the premier patient advocacy organization devoted to solving the mystery of lupus, a devastating autoimmune condition where the immune system attacks organs throughout the body, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus. Learn more about the Lupus Foundation of America at lupus.org. 

      Contact:

      Mike Donnelly
      [email protected]
      (202) 349-1162

      SOURCE Lupus Foundation of America, Inc.

      Modal title

      Also from this source

      Lupus Foundation of America Honors Prestigious Lupus Research Awardees at the Evelyn V. Hess Reception

      Lupus Foundation of America Honors Prestigious Lupus Research Awardees at the Evelyn V. Hess Reception

      The Lupus Foundation of America (LFA) honored three exceptional lupus researchers at the 2026 Evelyn V. Hess Reception. Mary (Peggy) K. Crow, MD,...

      Lupus Foundation of America Showcases New Research Advancing Lupus Diagnosis and Care at American College of Rheumatology Convergence 2026

      Lupus Foundation of America Showcases New Research Advancing Lupus Diagnosis and Care at American College of Rheumatology Convergence 2026

      The Lupus Foundation of America (LFA) and investigators funded through the Foundation's robust research grant programs will showcase new findings...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.